ONO Pharmaceutical
↗Osaka, Japan (Chuo-ku)
Ono Pharmaceutical Co., Ltd. is a leading Japanese R&D-oriented pharmaceutical company founded in 1717 with over 300 years of history dedicated to advancing human health. The company is an immuno-oncology specialist that researches, develops, manufactures, and sells prescription pharmaceuticals and diagnostic reagents. With consolidated operations spanning multiple continents, ONO focuses on breakthrough therapies for high unmet medical needs across oncology, immunology, neurology, and specialty medicine therapeutic areas. The company achieved particular prominence through its pioneering work in immune checkpoint inhibition and maintains significant partnerships with global pharmaceutical leaders to commercialize its innovations worldwide.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Immuno-oncology, Specialty Therapeutics
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3.19B-$3.4B
Founded:1717
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Investors:Harvard University (joint research and drug development agreement, 2024)
STOCK
Exchange:Tokyo Stock Exchange (TSE)
Ticker:4528 (TSE), OPHLY (OTC), OPHLF (NASDAQ)
Market Cap:$6.0B
PIPELINE
Stage:Phase 1-Phase 3
Lead Drug Stage:Phase 3 and Commercial
Modalities:Monoclonal antibody, Small molecule, BTK inhibitor, KIT inhibitor, BRAF inhibitor, EP4 antagonist, S1P5 receptor agonist, RNA-targeted therapy
Active Trials:15
Trial Phases:Phase 1: 3 | Phase 2: 7 | Phase 3: 5 | Phase 4: 2
FDA Approvals:12
EMA Approvals:8
CORPORATE STRUCTURE
Subsidiaries:Deciphera Pharmaceuticals Inc. (wholly-owned, acquired June 2024), ONO Pharma USA, Inc.
Key Partnerships:Bristol-Myers Squibb, Harvard University, Ionis Pharmaceuticals, Vertex, PRISM BioLab
COMPETITION
Position:Challenger
Competitors:Bristol-Myers Squibb, Merck & Co., Pfizer, Roche, Novartis, Takeda, Daiichi Sankyo, Astellas +7 more
LEADERSHIP
Key Executives:
Gyo Sagara - Representative Director, Chairman and Chief Executive Officer
Toichi Takino - Representative Director, President and Chief Operating Officer
Toshihiro Tsujinaka - Representative Director, Executive Vice President
Kunihiko Ito - President and CEO, ONO Pharma USA
Mitsunobu Tanimoto - Executive Vice President
David Trexler - Chief Commercial Officer & Board Member (US)
Kiyoaki Idemitsu - Executive Officer / Executive Director, Clinical Development
Scientific Founders:Tasuku Honjo
Board Members:Gyo Sagara (Chairman/CEO), Toichi Takino, Toshihiro Tsujinaka, Masao Nomura (Outside Director), Akiko Okuno (Outside Director), Shusaku Nagae (Outside Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ONO Pharmaceutical. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.